Journal of Nuclear Medicine Technology 2001: Vol 29 Index

7 Pages·2001·1.5 MB·English

2001 Author Index
Note: (ab) represents abstract Costedio. J. 1567(ab) Hichwa. RD. 1553(ab)
Coulston. CH. 161 Hnatowich. DJ. 1612(ab)
A Coutinho. B. 1506(ab) Hung. JC. 1524(ab), 1571(ab). 1574(ab).
Cservenyak. T. 1522(ab) 1585(ab), 1610(ab)
Aarsvold. JN. 1512(ab). I525(ab)
Cuklanz. EJ. 53, 202
Aburano, T. 1579< ab) I
Adams. KH. I56l(ab) D
Adler. LP. 1582(ab) Ireland. LA. 1505(ab). 1552(ab)
Afriyie. MO. 1515(ab). 1581(ab) Dalipaj. MM. 1502(ab). 161 l(ab) Irvine. P. 1502(ab). 161 l(ab)
Agerskov, L. 1575(ab) Das. SK. 1527(ab) Ishiguro. M. 1513(ab)
Ahlberg. A. 1501(ab). 1551 (ab) Dawadi. BR. 37 Ishikawa, Y. 1579(ab)
Alavi. A. 1564(ab) DeGreet. M. 1565(ab) Ishizu. K. 1587(ab)
Allman. KC. 1506(ab) Delbeke. D. 1518(ab) Itti. E. 1609(ab)
Alonso. O. 152. 1519(ab) Delpassand. E. 1555(ab). 1572(ab) Iverson. BC. 1524(ab). 1571 (ab)
Derango, A. 1516(ab)
Al-Saeed. T. 1567(ab)
Amin. K. 30 Dodge. RM. 1607.2(ab) J
Doggart. MJ. 1611 (ab)
Anliker. MR. 1604(ab) Jacobson. MS. 1574(ab). 1610(ab)
Donovan. P. 193
Anstett. F. 1504(ab) Jensen. M. 1575(ab)
Douglass. SA. 1608(ab)
Aoun. G. 1501(ab) Johnson. B. 169. 205
Dresel. S. 1507(ab). 1514(ab)
Armbrust-Henrich. H. 1508(ab) Johnson. K. 1607.2(ab)
Armstrong. J. 1502(ab) Duggan. JE. 1506(ab) Johnson. SG. 151 l(ab)
Arroyo. AJ. 1528(ab) Dyckman. W. 1551 (ab)
Assaei. R. 1558(ab). 1559(ab) E K
B Elgazzar. AH. 1567(ab) Kaplen. J. I589(ab)
Baehre. M. 1580(ab). 1584(ab) Elkamhawy. AA. 183 Kappas. R. 1576(ab)
Bakker. H. 1570(ab) Elsaid. M. 1567(ab) Karesh. SM. 1520(ab)
Bander. NH. I521(ab) Ennow. K. 1575(ab) Kashiba. A. 1579(ab)
Barrow. SA. 1560<ab). 1563(ab) Erwin. WD. 12. 15l6(ab) Katoh. A. 1513(ab)
Bartenstein. P. 1508(ab) Espasandin. J. 152 Kebede. Y. 1602(ab)
Kelly. GT. 1505(ab). 1552
Beretta. M. 1519(ab) F
Keppler. JS. 173
Berthold. T. 1522(ab)
Bhargava. KK. 1515(ab) Fahey, FH. 1582(ab) Kerchenfaut. KW. 1603(ab)
Bitner. SJ. 197 Farrell. M. 1522(ab) Kiefer. V. 154. 189. 193
Blumenfeld. H. 1562(ab) Feam. C. 1574(ab) Kikukawa. K. 1513(ab)
Boerman. O. 1570{ ab) Fielding. HW. 1529(ab) Kim. BY. 30
Bohuslavizki. KH. 50 Fischman. AJ. 1560(ab). 1563(ab) Kim. EE. 151 l(ab)
Bolus. NE. 67. 143 Fleming, R. 1501 (ab) King. LD. 1589(ab)
Bonab, AA. 1563(ab) Fram. D. 1551 (ab) King. MA. 1607(ab)
Borges-Neto, S. 1503(ab) France. M. 1566(ab) Knudsen. GM. 1526(ab). 1561 (ab)
Brake. SE. 197 Freeman. J. 1562(ab) Koenders. E. 1570(ab)
Bray. DM. 15861ab) Frodl. GS. 1610(ab) Koga. S. I5l3(ab)
Brinkbaeumer. K. 1507(ab). 1514(ab) Fujita. T. 1587(ab) Kohlhorst. L. 1523(ab)
Kok. PJ. 1565(ab)
Britt. C. 1522( ab) G Konishi. J. 1587(ab)
Brown. ML. I566(ab)
Bruno. A. 1588< ab) Gansen. DN. 1585(ab) Koslowsky. IL. 197
Bush. V. 1506( ab) Gerundini. P. 1588(ab) Kostakoglu. L. 1521 (ab)
Bybel. B. 30 Gifford. HC. 1607(ab) Kruger. RL. 79
Gladding. RL. 1564(ab) Kuji. I. 1521 (ab)
C Goldsmith. SJ. 1521 (ab) Kurdziel. K. I589(ab)
Carlson. KC. 1572(ab) Gough. J. 1604(ab), 1607.1 (ab) Kuzniecky. R. 1527(ab)
Carr. B. 1566(ab) Graham. MM. I505(ab). 1552(ab). 1553(ab). L
Castellani. M. 1588(ab) 1568(ab)
Cezar. RB. 1609(ab) Grant. SF. 1525(ab) Lago. G. 152
Chandna. H. 183 Grass. MM. 40. 1509(ab) Le. PH. 1606(ab)
Chen. CH. 1583(ab) Griff. M. 1522(ab) Lehmberg. O. 50
Clark. JA. 1553(ab) Groch. MW. 12. 1516(ab) Leo. R. 1588(ab)
Clark. M. 1576(ab) Leong. LK. 79
H
Clarke. M. 136. 172 Leveque. F. 1581 (ab)
Clermont. DA. 1553(ab> Hackett. MT. 189. 1517(ab). !554<ab), Licho. R. 1606(ab), 1607(ab). 1612(ab).
Coates. DM. 1523<ab) 1556< ab). 1557(ab) 1613(ab)
Coleman. RE. 1503(ab) Hahn. K. 1507(ab). 1514(ab) Lin. HD. 1578(ab). 1583(ab)
Collins. JA. 154. 1554(ab). 1556(ab). Halkar. RK. 1513(ab). 1525(ab) Lin. KP. 1578(ab). 1583(ab)
1557(ab) Hammerlund. LA. 1516(ab) Lincoln. MT. 1506(ab)
Collins. L. I556(ab) Hanson. MW. 1503(ab) Liu. J. 1527(ab)
Connolly. SA. I560(ab) Harkness. BA. 1. 59. 135. 171, 1582(ab) Liu. K. 1607.1 (ab). 1607.2(ab). 1614(ab)
Conway. AA. 1504(ab) Harrison. S. 1501 (ab). 1551 (ab) Liu. RS. 1578(ab). 1583(ab)
Corsi. M. 1562(ab) Heidary. A. 1558(ab) Livni. E. 1563(ab)
Corstens. F. 1565(ab). 1570<ab) Heller.GV. 1501(ab). 1551(ab) Loutfi. I. 1529(ab)
10A Journal of Nuclear Medicine Technology
2001 Author Index
Note: (ab) represents abstract Costedio. J. 1567(ab) Hichwa. RD. 1553(ab)
Coulston. CH. 161 Hnatowich. DJ. 1612(ab)
A Coutinho. B. 1506(ab) Hung. JC. 1524(ab), 1571(ab). 1574(ab).
Cservenyak. T. 1522(ab) 1585(ab), 1610(ab)
Aarsvold. JN. 1512(ab). I525(ab)
Cuklanz. EJ. 53, 202
Aburano, T. 1579< ab) I
Adams. KH. I56l(ab) D
Adler. LP. 1582(ab) Ireland. LA. 1505(ab). 1552(ab)
Afriyie. MO. 1515(ab). 1581(ab) Dalipaj. MM. 1502(ab). 161 l(ab) Irvine. P. 1502(ab). 161 l(ab)
Agerskov, L. 1575(ab) Das. SK. 1527(ab) Ishiguro. M. 1513(ab)
Ahlberg. A. 1501(ab). 1551 (ab) Dawadi. BR. 37 Ishikawa, Y. 1579(ab)
Alavi. A. 1564(ab) DeGreet. M. 1565(ab) Ishizu. K. 1587(ab)
Allman. KC. 1506(ab) Delbeke. D. 1518(ab) Itti. E. 1609(ab)
Alonso. O. 152. 1519(ab) Delpassand. E. 1555(ab). 1572(ab) Iverson. BC. 1524(ab). 1571 (ab)
Derango, A. 1516(ab)
Al-Saeed. T. 1567(ab)
Amin. K. 30 Dodge. RM. 1607.2(ab) J
Doggart. MJ. 1611 (ab)
Anliker. MR. 1604(ab) Jacobson. MS. 1574(ab). 1610(ab)
Donovan. P. 193
Anstett. F. 1504(ab) Jensen. M. 1575(ab)
Douglass. SA. 1608(ab)
Aoun. G. 1501(ab) Johnson. B. 169. 205
Dresel. S. 1507(ab). 1514(ab)
Armbrust-Henrich. H. 1508(ab) Johnson. K. 1607.2(ab)
Armstrong. J. 1502(ab) Duggan. JE. 1506(ab) Johnson. SG. 151 l(ab)
Arroyo. AJ. 1528(ab) Dyckman. W. 1551 (ab)
Assaei. R. 1558(ab). 1559(ab) E K
B Elgazzar. AH. 1567(ab) Kaplen. J. I589(ab)
Baehre. M. 1580(ab). 1584(ab) Elkamhawy. AA. 183 Kappas. R. 1576(ab)
Bakker. H. 1570(ab) Elsaid. M. 1567(ab) Karesh. SM. 1520(ab)
Bander. NH. I521(ab) Ennow. K. 1575(ab) Kashiba. A. 1579(ab)
Barrow. SA. 1560<ab). 1563(ab) Erwin. WD. 12. 15l6(ab) Katoh. A. 1513(ab)
Bartenstein. P. 1508(ab) Espasandin. J. 152 Kebede. Y. 1602(ab)
Kelly. GT. 1505(ab). 1552
Beretta. M. 1519(ab) F
Keppler. JS. 173
Berthold. T. 1522(ab)
Bhargava. KK. 1515(ab) Fahey, FH. 1582(ab) Kerchenfaut. KW. 1603(ab)
Bitner. SJ. 197 Farrell. M. 1522(ab) Kiefer. V. 154. 189. 193
Blumenfeld. H. 1562(ab) Feam. C. 1574(ab) Kikukawa. K. 1513(ab)
Boerman. O. 1570{ ab) Fielding. HW. 1529(ab) Kim. BY. 30
Bohuslavizki. KH. 50 Fischman. AJ. 1560(ab). 1563(ab) Kim. EE. 151 l(ab)
Bolus. NE. 67. 143 Fleming, R. 1501 (ab) King. LD. 1589(ab)
Bonab, AA. 1563(ab) Fram. D. 1551 (ab) King. MA. 1607(ab)
Borges-Neto, S. 1503(ab) France. M. 1566(ab) Knudsen. GM. 1526(ab). 1561 (ab)
Brake. SE. 197 Freeman. J. 1562(ab) Koenders. E. 1570(ab)
Bray. DM. 15861ab) Frodl. GS. 1610(ab) Koga. S. I5l3(ab)
Brinkbaeumer. K. 1507(ab). 1514(ab) Fujita. T. 1587(ab) Kohlhorst. L. 1523(ab)
Kok. PJ. 1565(ab)
Britt. C. 1522( ab) G Konishi. J. 1587(ab)
Brown. ML. I566(ab)
Bruno. A. 1588< ab) Gansen. DN. 1585(ab) Koslowsky. IL. 197
Bush. V. 1506( ab) Gerundini. P. 1588(ab) Kostakoglu. L. 1521 (ab)
Bybel. B. 30 Gifford. HC. 1607(ab) Kruger. RL. 79
Gladding. RL. 1564(ab) Kuji. I. 1521 (ab)
C Goldsmith. SJ. 1521 (ab) Kurdziel. K. I589(ab)
Carlson. KC. 1572(ab) Gough. J. 1604(ab), 1607.1 (ab) Kuzniecky. R. 1527(ab)
Carr. B. 1566(ab) Graham. MM. I505(ab). 1552(ab). 1553(ab). L
Castellani. M. 1588(ab) 1568(ab)
Cezar. RB. 1609(ab) Grant. SF. 1525(ab) Lago. G. 152
Chandna. H. 183 Grass. MM. 40. 1509(ab) Le. PH. 1606(ab)
Chen. CH. 1583(ab) Griff. M. 1522(ab) Lehmberg. O. 50
Clark. JA. 1553(ab) Groch. MW. 12. 1516(ab) Leo. R. 1588(ab)
Clark. M. 1576(ab) Leong. LK. 79
H
Clarke. M. 136. 172 Leveque. F. 1581 (ab)
Clermont. DA. 1553(ab> Hackett. MT. 189. 1517(ab). !554<ab), Licho. R. 1606(ab), 1607(ab). 1612(ab).
Coates. DM. 1523<ab) 1556< ab). 1557(ab) 1613(ab)
Coleman. RE. 1503(ab) Hahn. K. 1507(ab). 1514(ab) Lin. HD. 1578(ab). 1583(ab)
Collins. JA. 154. 1554(ab). 1556(ab). Halkar. RK. 1513(ab). 1525(ab) Lin. KP. 1578(ab). 1583(ab)
1557(ab) Hammerlund. LA. 1516(ab) Lincoln. MT. 1506(ab)
Collins. L. I556(ab) Hanson. MW. 1503(ab) Liu. J. 1527(ab)
Connolly. SA. I560(ab) Harkness. BA. 1. 59. 135. 171, 1582(ab) Liu. K. 1607.1 (ab). 1607.2(ab). 1614(ab)
Conway. AA. 1504(ab) Harrison. S. 1501 (ab). 1551 (ab) Liu. RS. 1578(ab). 1583(ab)
Corsi. M. 1562(ab) Heidary. A. 1558(ab) Livni. E. 1563(ab)
Corstens. F. 1565(ab). 1570<ab) Heller.GV. 1501(ab). 1551(ab) Loutfi. I. 1529(ab)
10A Journal of Nuclear Medicine Technology
M Petersen. DW. 1568(ab) Swanston. NM. 1555<ab)
Pham. HL. 1608(ab). I609(ab) Sy. W. I576(ab)
MacDonald. J. 32
Pierre. J. 158Kab)
Madras. BK. I563(ab) T
Pinsky. T. I528(ab)
Madsen. M. 15f>8(ab)
Podoloff. D. 151 Kab). I555(ab). 1573<ab) Tadamura. E. 1587(ab)
Maeda. DW. I371(ab)
Ponto, LL. 1553( ab) Tanhehco. T. I562(ab)
Magoun. S. 84 Porter. DV. I577(ab) Thomas. E. 52. 87. 163. 201
Mahoney. DW. 1571 (ab> Potter. CB. I60l(ab) Thompson. MA. 61. 137
Mann. A. 1501 (ab). 1551 (ab>
Pretorius. H. 16l3(ab) Thomsen. G. 1526(ab)
Mann. EG. I6l2(ab). 1613<ab)
Primiano. C. 150Kab) Thomson. LE. 1506(abi
Mar. MV. 151 Kab)
Prowsner. RA. 1560(ab) Timpe. JT. 1572(ab)
Martin. WH. 1518<ab) Pugliese. PV. 1515<ab). 158l(ab) Tomas. MB. 1515(ab)158Kab)
Martinez. M. 152 Toulouse. KA. 1524(ab). 1571 <ab>
Martiny, L. I56l(ab)
R Toyada. H. 1587(ab)
Matrow. CM. I607(ab)
Toyama. H. 1513<ab)
Matsumoto. K. 1587(ab) Ravin. PD. 16l3(ab) Turkington. TG. 4
Mays. TL. 1574(ab) Rezvani. K. 1608(ab)
McCook. B. I566(ab) Rich. T. 30 U
McGill. CC. 1501 (ab) Richmond. JC. 1553< ab> Uffelman. W. 56. 88. 168. 205
McPherson. JD. 1569<ab>. I572<ab> Richter. E. I580(ab). 1584<ab)
Uranga. AP. 1562( ab)
Measel. DL. I512(ab) Riggert. J. I568(ab)
Meeuwis. AP. I565(ab) Robinson. E. 46 V
Meltzer. P. I563(ab) Rosen. J. 1566(ab) Vallabhajosula. S. 152l(ab)
Menda. Y. 1553( ab) Rothtusz. BC. I525(ab) Varzegar. R. 1558(ab). I559iab)
Merani. A. 1611 <ab) Ruddy. TD. 1502(ab). 161 Kab) Vehling. D. 1508<ab)
Mishkin. FS. I608(ab). I609(ab)
Videbtek. C. 1526<ab)
Mitchell. B. 84 S Vila. R. 1519(ab)
Moorin. R. 22 Sajdak. RA. I520<ab> Voltini. F. I588(ab)
Morano. G. 151 ()<ab). !562(ab). I586(abi Sandler. MP. 1518(ab) Votaw. D. I588(ab)
Morgan. E. 1551 (ab >
Sato. J. I579(ab)
Morgan. MM. 159 \Y
Sawai. T. 1513( ab)
Mountz. JM. 1527( ab) Schelper. LF. l58(Kab). 15841 ab) Wang. JK. I583(ab)
Mut. F. I5l9(ab) Schiavini. M. 1588(ab» Ward. CA. 1553( ab)
N Schreckenberger. M. 1508t ab) Washburn. SA. 1518(ab)
Schunk. K. I508lab) Waterstram-Rich. K. 3. 60
Natnislo. LJ. I606(ab) Schwartz. P. 1510< ab) Watkins. GL. 1553t ab)
Narayanan. MV. 1607(ab) Sechrist. S. 86 Weaver. JP. I606(ab)
Neumann. DR. 30 Seibyl. JP. 1510(ab). 1562(ab). 1586(ab) Wendt. R. 1555(ab). 1573(ab)
Neurath. M. 1508(ab) Seliger. JD. 1605(ab) Wierzbinski. RS. 84. 1556<ab). I557(ab)
Niblack. EM. I509(ab) Seniaan. H. 1528(ab) Wiseman. GA. 1577(ab). 1585<ab)
Nunez. M. 15l9(ab) Senda. K. 1513( ab) Wisniewski. G. 1586( ab)
O Senglaub. TM. 1520(ab) Withrow. KA. 1607.Kab)
Seo. 1. 1576( ab) Worsley. T. 40
O'Connor, MK. 79 Sheetz. MM. I566(ab) Wu. LC. 1578<ab). 1583(ab)
Ojha. BC. I527(ab) Shih. W. 1517<ab)
Y
Omar. AM. 1567(ab) Shih. W-J. 46. 84. 154. 189. 193
OstrolY. R. 1562(ab) Shirakawa. S. 1513<ab) Yokoyama. K. 1513( ab)
Oven. WJ. I565(ab» Shuke. N. I579<ab> Yu. CL. 1578(ab). 1583(ab)
Smith. EO. 151 (>< ab)
P Smith. HC. I582(ab) Z
Pad. H. 1614(ab) Smith-Jones. P\l. 152Kab) * Zachary. RA. 16l2(ab)
Pagnanelli. RA. I503(ab) Sorensen. A. I575(ab) Zajko. A. I566(ab)
Palestro. CJ. 15l5(ab). 158Kab) Spieth. ME. I604(ab). 1607.Kab). Zakeri. F. 1558(ab)
Patel. Y. 1528(ab> I607.2(ab). 1614(ab) Zeng. W. 156
Patton. JA. 1518<ab) Stachowiak. A. 1573< ab) Zhuang. H\l. 1564(ab)
Pavlicek. P. 1522(ab) Stadalnik. RC. I524(ab) Zimmer. AM. 1569iab>. 1572tab)
Pedersen. HS. 1575(ab) Stahr. K. 156Kab) Zito. F. I588(ab)
Pepper. R. 1523(ab) Stillwell. DS. 1509(ab) Zoe. H. 152Kab)
Perez. A. I5l()(ab) Sullivan. A. 56. 88 Zubal. IG. 1562<ab). 1586(ab)
11A
Volume 29. Number 4, December 2(M)I
2001 Subject Index
Note: (ub) represents abstract Chromosomes, aberrations, peripheral blood PET
lymphocytes, radiation workers in Iran. bowel wall inflammation. I5()8(ab)
1559(ab) comparison with separate acquisition
Chylothorax, lymphoscintigraphy in. l'l,mTc protocol. 1503(ab)
Adenosine
filtered colloid. 30 dual-time point imaging, pulmonary
caffeine effects, list of food and drugs
Coincidence detection camera nodules. I564(ab)
containing. I605(ab)
functional anatomical mapping, with inde¬ w,"Tc HMPAO SPECT and. epilepsy.
escalating dose, hyperreactive airway dis¬
terminate PET scans. 1517(ab) I527(ab)
ease. 1552< ab)
ongoing exposure to 511 keV photons. oncology and cardiology in same pa¬
stress testing, caffeine effects. I505(ab)
sodium iodide crystal. PET. 1515(ab) tient. I553(ab)
Artifacts, motion, OSEM and FBP SPECT
partial volume effect, objects with similar quantitative tumor analysis. I589(ab)
reconstruction algorithms, I579(ab)
axial diameter. 1581 (ab) uptake, glucose level, age and fasting
Attenuation correction
thick sodium iodide crystal, performance effects, I565(ab)
nonuniform and uniform, comparative
evaluation. I5l6(ab) Food and Drug Administration (FDA),
analysis. PET and SPECT. I586(ab)
Coincidence imaging PET drugs, 173
pre and post injection transmission. FDG
diagnosis of hibernating myocardium.
PET brain studies. 1588<ab)
I507(ab) G
B gamma camera. 1514(ab)
Gallbladder disease, evaluation and man¬
quantitative tumor analysis. FDG PET,
Background equivalent radiation time, agement. gallbladder ejection fraction.
1589(ab)
communication of. 156 I602(ab)
Collimation, collimators, medium energy.
Biodistribution. FDG PET. glucose level. Gamma camera, coincidence imaging with,
1,11 thyroid uptake using gamma cam¬
age and fasting effects, 1565(ab) 1514< ab)
era. 1576(ab)
Biostatistics, epidemiology for the nuclear G-Codes, for PET. 173
Cranioplasty, metallic, brain SPECT arti¬
medicine technologist, 143 Glomerular filtration rate (GFR), determi¬
facts with, 189
Bone-imaging agent nation. plasma sampling frequency and
CT, instrumentation and quality control, in
extravasation of. ipsilateral lymph nodes range. Excel Solver Model. I568(ab)
2(X) 1. 12
secondary to. 154 Glucose metabolism, FDG SPECT for.
localization of w,"Tc HMDP. extraskeletal I) myocardial viability, I506(ab)
myxoid chondrosarcoma. 84
Bone scan, pelvic. OSEM reconstruction Dopamine transporters, density, striatum. H
compared to FBP in. 1513(ab) "C altropane PET, I563(ab)
Bone scintigraphy Dose calibration. FDG. error dispensing, Hepatocellular cancer, infusing ""Y thera-
idiopathic uptake of w"‘Tc MDP. hepatic. I575(ab) spheres. technical aspects. I566(ab)
32 Dosimetry, radiation, monoclonal antibody High-performance liquid chromatography
ipsilateral lymph nodes, left hand. 154 mI J59I versus '*’Y J591, I52l(ab) ' (HPLC), size exclusion, radiochemical
Book reviews Dual isotope imaging, simultaneous, photon purity assessment. I569(ab)
Nuclear Hepatology: A Textbook of Hepa¬ energy recovery technique, 1504(ab) Hospital Outpatient Prospective Payment
tobiliary Diseases, 50 Duodenogastric reflux, w"Tc tetrofosmin. System (HOPPS), PET and, 173
Nuclear Medicine Procedure Manual myocardial SPECT, 193 Hy brid camera
background resolution and system effi¬
2000-2002, 86
E ciency. various rebinning parameters.
Brain imaging, SPECT. artifacts with metal¬
lic cranioplasty, 189 Editor's page, I. 59. 135. 171 I580(ab)
Breast scintigraphy, miraluma in. adjunct to Electroconvulsive therapy (ECT), cerebral PET/SPECT. fractions of scatter and dis¬
mammography, 1510< ab) blood flow changes during. 9*"Tc HM¬ turbing radiation. 1584(ab)
PAO brain SPECT. 1562(ab) Hyperreactive airway disease, escalating
C Epidemiology, for the nuclear medicine dose of adenosine in, I552(ab)
Caffeine technologist, 143. 150
adenosine stress testing and. 15()5<ab) Epilepsy, w,”Tc HMPAO SPECT. FDG PET I
list of foods containing. I605(ab) and. localization, 1527(ab) Image analysis, DICOM. MayoImageX Ac¬
Carbon-11 altropane. PET. dopamine trans¬ Extravasation, bone-imaging agent, ipsilat¬ tive X. I577(ab)
porter density. striatum, 1563(ab) eral lymph nodes secondary to. 154 Image processing, brain tissue classification.
Cardiac imaging parametric analysis, 1578< ab)
F
acute rest myocardial, impact of coronary Image reconstruction, SPECT. uniformity
flow restoration. 1551 (ub) Filtered backprojection (FBP), compared requirements for. 79
dipyridamole and adenosine. w"Tc sesta- with OSEM Inferoposterior artifact, minimum detect¬
" mibi SPECT. 1501 (ab) motion artifacts. 1579(ab) able defect thickness for SPECT, 183
FDG or w"Tc. hint badge readings in the pelvic bone scan. 1513(ab) Instrumentation
90's, I520(ab) uniformity requirements for SPECT image PET. introduction to. 4. 19
simultaneous dual isotope, photon energy reconstruction. 79 quality control and. SPECT in 2(X)1, 12
recovery technique. I504(ab) Fluoride-18 altanserin. metabolite assay. Iodine-131
Cause and effect relationships, nuclear FDG PET. human plasma. 1561 < ab) patients treated with, radiation exposure to
medicine, 143 Fluorodeoxyglucose (FDG) family members. I60l(ab)
Centralized management, corporate nuclear axillary uptake, whole-body studies, injec¬ therapy, hospitalized patient, safety pre¬
medicine, 40 tion protocol in. 1512(ab) cautions with. 61
Cerebral blood flow, changes, during ECT, dose calibrator nonlinearity, error in dis¬ thyroid uptake, gamma camera with me¬
WmTc HMPAO brain SPECT, I562(ab) pensing. I575(ab) dium energy collimator. I576(ab)
Certification examination, NMTCB. com¬ LAL inhibition testing, low pH range ef¬ Iodine-123 fi-CIT, diagnosis. Parkinson's
puterized, 37 fects. I6l()(ab) disease, 1526( ab)
12A Journal of Nuclear Medicine Technology
Iterative reconstruction, image fusion, ab¬ Myocardial viability, FDG SPECT. dex¬ Pheochromocytoma, recurrent, FDG PET
domen and pelvis, SPECT, I573(ab) trose/insulin infusion versus oral glucose imaging, 1560(ab)
loading. 1506(ab) Picture archiving computer system
J Myxoid chondrosarcoma, extraskeletal. lo¬ (PACS), PET image viewing. JAVA
calization of WnTc HMDP in. 84 technology, 1583(ab)
Joint Review Committee on Educational
Positrons, introduction to PET instrumenta¬
Programs in Nuclear Medicine Tech¬
N tion. 4
nology (JRCNMT), 53, 202
Nuclear medicine Pulmonary nodules, dual time point imag¬
K corporate, centralized management model, ing, FDG PET. 1564(ab)
40
Kidney function epidemiology for the technologist, 143 Q
GFR determination, plasma sampling fre¬ Nuclear medicine images, making slides
quency and range. Excel Solver for. 46 Quality control
Model, 1568(ab) Nuclear medicine technologists, qualifica¬ external test, minimum detectable defect
WmTc absolute uptake, pediatric values at tion as educators, 159 thickness for SPECT, 183
2-4 hours, 22 Nuclear Medicine Technology Certification improved. 9',mTc tetrofosmin, 1570(ab)
Kidney transplantation, postoperative radio¬ Board (NMTCB) instrumentation and. SPECT in 2001. 12
nuclide renography for, drawbacks, computerized certification examination. 37 Quantitative measurements, WnTc absolute
1567(ab) report, 52, 87, 163, 201 uptake, pediatric values at 2-4 hours,
Nuclear scintigraphy, thyroid measure¬ 22
L ments, in thyrotoxic patients, I528(ab)
Left ventricular ejection fraction, measure¬ R
ments, rest versus stress WmTc tetrofos- O
Radiation biology , terminology and, basic
min SPECT. 1502(ab) Occupational radiation exposure, risk asso¬
review. 67, 76
Liver, idiopathic uptake of WmTc MDP. ciated with, 137
Radiation exposure
bone scintigraphy, 32 Ordered-subsets expectation maximization
communication of, 156
Lower extremity, extraskeletal myxoid (OSEM)
family members, patients treated with ,3M,
chondrosarcoma, localization of ""Tc compared with FBP
1601(ab)
HMDP. 84 motion artifacts, 1579(ab)
reduction of, PET technologists, I522(ab)
Lymph nodes, ipsilateral, left hand, visual¬ pelvic bone scan, 1513<ab)
risk associated with. 137, 147
ization of, 154 SPECT image reconstruction techniques,
Radiation safety
Lymphoscintigraphy uniformity requirements for, 79
accident
WmTc filtered sulfur colloid, chylothorax, Osteomyelitis, digital subtraction technique
cytogenetic and immunological follow¬
30 for diagnosis, I603(ab)
up. 1558( ab)
WnlTc MIB1 and, sentinel lymph node sta¬
workers in Iran.chromosome aberrations
tus in melanoma, 152 P
in peripheral blood lymphocytes,
whole-body, with transmission scan,
Parametric imaging, brain tissue classifica¬ 1559(ab)
151 l(ab)
tion, segmentation technique for, communicating exposure, 156
1578(ab) "'I therapy, hospitalized patient. 61, 74
M
Parkinson's disease risk for medical workers. 137
MAA kits, shortage of, ventilation/perfusion diagnosis with ,23I /3-CIT, 1526<ab) Radiation therapy
scanning, 1612(ab) movement disorders, altropane SPECT basic biology concepts, 67
MRI, bone, localization of pain before spinal binding in, 1613(ab) patient precautions, hospitalized patient. 61
injection. 1606(ab) Partial volume effect, objects with similar Radioactive contamination, packages from
Maximum likelihood expectation maximi¬ axial diameter. 1581 (ab) radiopharmacy. 1554(ab)
zation, reconstruction with, median fil¬ Pediatric patients, ‘>9mTc absolute uptake, Radioisotopes, therapy doses, syringe fill
tering after, 1587(ab) 2-4 hours, 22 station for. 1585(ab)
Medical radiation workers, risk associated PET Radiolabeled antibody therapy, 1311 J591
with, 137 activity quantification. 1582(ab> versus J59I. radiation dosimetry.
Medicare, regulations and reimbursement for dopamine transporter density, striatum. 1521(ab)
PET. 173 altropane in, 1563(ab) Radiopharmaceuticals
Melanoma, sentinel lymph node status in, IXF altanserin in. human plasma. 1561 (ab) aseptic operations, design of PET isolator
WmTc MIBI and lymphoscintigraphy, FDG for. 1574(ab)
152 bowel wall inflammation, 1508(ab) routine radiochemical purity, kit failures,
Message from the President, 3, 60. 136. brain, pre and post injection transmis¬ 1572(ab)
172 sion measurement, 1588(ab) Radiopharmacy, radioactive contamination
Miraluma, use with dense breasts, adjunct to oncology and cardiology in same pa¬ in packages from, 1554(ab)
mammography, 1510(ab) tient, 1553(ab) Rebinning parameters, effects on back¬
Monoclonal antibodies (MAb), radiochemi¬ quality after general nuclear medicine ground resolution and system efficiency,
cal purity assessment. HPLC. 1569(ab) scan with ""Tc, 1555(ab) hybrid camera, 1580(abl
Motion correction, tomographic myocardial recurrent pheochromocytoma, 1560(ab) Reconstruction, median filtering after, maxi¬
perfusion imaging, 1611 (ab) hybrid cameras, fractions of scatter and mum likelihood expectation maximiza¬
Multimodality imaging, recurrent thyroid disturbing radiation. I584(ab) tion. 1587( ab)
cancer patients, 1609(ab) instrumentation, introduction to, 4 Reimbursement, for PET, 173
Myocardial perfusion imaging isolator, design, for aseptic processing. Renal plasma flow, ""Tc MAG3 estima¬
SPECT !574(ab) tion, correlation of blood ERPF and.
minimum detectable defect thickness mobile, technologist exposures on, 1608(ab)
for, 183 1523(ab) Renography
""Tc tetrofosmin duodenogastric reflux, regulatory and reimbursement environ¬ "Tc MAG3 bolus arrival, clearance esti¬
193 ment, 173, 180 mates. 1525(ab)
tomographic, method of motion correction, whole-body, disturbed viewing systems radionuclide, after kidney transplant, draw¬
1611 (ab) based on JAVA. 1583(ab) backs of. 1567(ab)
Volume 29, Number 4, December 2001 13A
s T Technetium-99m Neotect, imaging, solitary
pulmonary nodules, 1607(ab)
Salivary glands, scintigraphy, semiquantita- Technetium-99m
Technetium-99m serum albumin, in-house
tive analysis for uptake and clearance. brain SPECT. artifacts with metallic cra¬
preparation, 1571 (ab)
1529(ab) nioplasty. 189
Technetium-99m tetrofosmin
Scatter correction, scintimammography. general nuclear medicine scan with. FDG
duodenogastric reflux on myocardial
1519(ab) PET procedures after. 15550*)
SPECT. ejection fraction and. 193
Scintimammography. scatter correction for. routine radiochemical purity, kit failures.
improved quality control. 1570<ab)
15l9(ab) 1572(ab) SPECT. rest versus stress left ventricular
Sentinel nodes Technetium-99m DMSA ejection fraction. 1502(ab)
imaging absolute uptake, pediatric values at 2-4 Technologist News, 56. 88. 164. 205
breast mapping studies. 1509<ab) hours. 22 Thyroid cancer
evaluation of postoperative specimens. early evaluation, urinary tract infection. mI radiation therapy, patient precautions.
1517(ab) 1530(ab), s 61
status in melanoma, lymphoscintigraphy Teehnetium-99m ECD, stabilized stored in recurrent, multimodality assessments in.
and ^mTc MIBl' 152 syringes, 197 1609(ab)
Slides, for nuclear medicine images. 46 Technetium-99m filtered sulfur colloid, Thyroid volume, measurements, in thyro¬
Sodium iodide crystal, ongoing exposure to lymphoscintigraphy with, chylothorax. toxic patients, 1528( ab)
511 keV photons and. hybrid PET sys¬
30 Transmission tomography, nonuniform and
tem. 1515(ab)
Technetium-99m GSA, purity and stability, uniform correction. PET and SPECT.
SPECT
chromatographic method for evaluation. I586(ab)
altropane. Parkinson's disease. 1613(ab)
I524(abi
bone, localization of pain before spinal U
Technetium-99m HMDP, localization of.
injection. I606(ab) extraskeletal myxoid chondrosarcoma, Ultrasonography, thyroid measurements, in
brain artifacts, with metallic cranioplasty. 84 thyrotoxic patients, I528(ab)
189 Technetium-99m HMPAO Uniformity, SPECT image reconstruction.
image1 5f7u3si0o*n), abdomen and pelvis. brain dSuPriEngC TE.C cTe.r eIb5r6al2 (balbo)o d flow changes UrinaFrBvP traancdt OinSfEeMcti otenc, henairqlvu eesv, a7l9u ation.
imagem reenctso nfsotrr.u cFtBioPn ,a nudn iOfoSrmEMity treecqhu¬i re¬ stabilized, stored in syringes. 197 w"Tc DMSA. 1530(ab)
niques. 79 Technetium-99m MAG3 V
instrumentation and qualitv control, in bolus arrival time, clearance estimates. Ventilation/perfusion scanning, MAA kits
2001. 12. 20 1525(ab) for. emergent shortage for. 1612(ab)
WmTc HMPAO. FDG PET and. epilepsy. camera-based estimation, correlation of Ventilation system, internal bacteria filter.
15270*) blood ERPF. renal plasma flow. l v,Xe contamination in. 1556(ab)
myocardial perfusion 1608(ab)
minimum detectable defect thickness. Technetium-99m MDP. idiopathic hepatic X
183 uptake, 32 Xenon-133
WmTc letrofosmin duodenogastric reflux. Technetium-99m M1BI contamination, ventilation system's inter¬
193 acute rest myocardial perfusion imaging. nal bacteria filter. 1556(ab)
Stochastic radiation, effects. 67 coronary flow in. 1551 tab) leakage, used and unused vials, 1557(ab)
Sulfur colloid, filtered, lymphoscintigraphy dipyridamole and adenosine with, cardiac
Y
in chylothorax, 30 imaging, 1501 (ab)
Syringes, stability and storage. ‘WmTc lymphoscintigraphy and. sentinel lymph Yttrium-90, theraspheres. infusing into hepa¬
HMPAO and ECD. 197 node status in melanoma. 152 tocellular cancer. 1556(ab)